These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33660106)

  • 1. Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.
    Kato Y; Yamamoto G; Watanabe Y; Yamane Y; Mizutani H; Kurimoto F; Seike M; Gemma A; Akagi K; Sakai H
    Int J Clin Oncol; 2021 Jun; 26(6):1065-1072. PubMed ID: 33660106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
    Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
    Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and PD-L1 Expression of
    Xu Z; Li H; Dong Y; Cheng P; Luo F; Fu S; Gao M; Kong L; Che N
    Onco Targets Ther; 2020; 13():6245-6253. PubMed ID: 32669854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
    Guisier F; Dubos-Arvis C; Viñas F; Doubre H; Ricordel C; Ropert S; Janicot H; Bernardi M; Fournel P; Lamy R; Pérol M; Dauba J; Gonzales G; Falchero L; Decroisette C; Assouline P; Chouaid C; Bylicki O
    J Thorac Oncol; 2020 Apr; 15(4):628-636. PubMed ID: 31945494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring
    Inno A; Bogina G; Settanni G; Salgarello M; Foti G; Pomari C; Picece V; Gori S
    Drug Target Insights; 2023; 17():110-113. PubMed ID: 37840886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Wong SK; Alex D; Bosdet I; Hughesman C; Karsan A; Yip S; Ho C
    Lung Cancer; 2021 Apr; 154():142-145. PubMed ID: 33667719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
    Heist RS; Shim HS; Gingipally S; Mino-Kenudson M; Le L; Gainor JF; Zheng Z; Aryee M; Xia J; Jia P; Jin H; Zhao Z; Pao W; Engelman JA; Iafrate AJ
    Oncologist; 2016 Apr; 21(4):481-6. PubMed ID: 27022036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
    Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
    Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
    Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report.
    Chen Z; Zhu F; Li C; Li J; Cheng B; Xiong S; Zhong R; Liang W; He J
    Ann Transl Med; 2021 Mar; 9(5):424. PubMed ID: 33842645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic
    Choudhury NJ; Schneider JL; Patil T; Zhu VW; Goldman DA; Yang SR; Falcon CJ; Do A; Nie Y; Plodkowski AJ; Chaft JE; Digumarthy SR; Rekhtman N; Arcila ME; Iasonos A; Ou SI; Lin JJ; Drilon A
    JTO Clin Res Rep; 2021 Jul; 2(7):100187. PubMed ID: 34590036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung Cancer with
    Fujino T; Suda K; Mitsudomi T
    Lung Cancer (Auckl); 2021; 12():35-50. PubMed ID: 34295201
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive analysis of
    Ai X; Yu Y; Zhao J; Sheng W; Bai J; Fan Z; Liu X; Ji W; Chen R; Lu S
    Ther Adv Med Oncol; 2022; 14():17588359221112474. PubMed ID: 35860830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
    Qiu T; Li W; Zhang T; Xing P; Huang W; Wang B; Chu L; Guo L; Liu X; Li Y; Ying J; Li J
    Clin Lung Cancer; 2018 Jul; 19(4):e391-e398. PubMed ID: 29338938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With
    Lau SCM; Perdrizet K; Fung AS; Mata DGMM; Weiss J; Holzapfel N; Liu G; Bradbury PA; Shepherd FA; Sacher AG; Feilotter H; Sheffield B; Hwang D; Tsao MS; Cheng S; Cheema P; Leighl NB
    JTO Clin Res Rep; 2023 Oct; 4(10):100562. PubMed ID: 37744308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
    Vuong HG; Ho ATN; Altibi AMA; Nakazawa T; Katoh R; Kondo T
    Lung Cancer; 2018 Sep; 123():76-82. PubMed ID: 30089599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline
    Jiao Y; Fang C; Yang Y; Shao L; Huang Y; Sun Q; Dong Y
    Onco Targets Ther; 2021; 14():2417-2421. PubMed ID: 33854337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.